Decreased expression of the INK4 family of cyclin-dependent kinase inhibitors in wilms tumor

Genes Chromosomes and Cancer

Volumn 29, Issue 1, 2000, Pages 63-69

  Arcellana Panlilio, Mayi Y ^a,b   Egeler, R Maarten ^a,b   Ujack, Eva ^a,b   Pinto, Alfredo ^a   Demetrick, Doug J ^a   Robbing, Stephen M ^a   Coppes, Max J ^a,b,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c ALBERTA CHILDREN'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DNA METHYLATION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; NEPHROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CARRIER PROTEINS; CELL CYCLE PROTEINS; CHILD; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P16; GENES, TUMOR SUPPRESSOR; HELA CELLS; HUMANS; MULTIGENE FAMILY; PILOT PROJECTS; PROGNOSIS; TUMOR SUPPRESSOR PROTEINS; WILMS TUMOR;

EID: 0033855507     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2264(2000)9999:9999<::AID-GCC1006>3.0.CO;2-L     Document Type: Article

References (24)

1. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE. 1994. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8:27-32.
2. Coppes MJ, Egeler RM 1999. Genetics of Wilms' tumor. Semin Urol Oncol 17:2-10.
3. Gazzeri S, Gouyer V, Vour'ch C, Brambilla C, Brambilla E. 1998. Mechanisms of p16INK4A inactivation in non small-cell lung cancers. Oncogene 16:497-504.
4. Gemma A, Takenoshita S, Hagiwara K, Okamoto A, Spillare E.A, McMemamin MG, Hussain SP, Forrester K, Zariwala M, Xiong Y, Harris CC. 1996. Molecular analysis of the cyclin-dependent kinase inhibitor genes p15INK4b/MTS2, p16INK4/MTS1, p18 and p19 in human cancer cell lines. Int J Cancer 68:605-611.
5. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA. 1995. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing Cancer Res 55:4531-4535.
6. Groeger AM, Caputi M, Esposito V, De Luca A, Bagella L, Pacilio C, Klepetko W, Giordano GG, Baldi F, Kaiser HE, Wolner E, Giordano A. 1999. Independent prognostic role of p16 expression in lung cancer. J Thorac Cardiovasc Surg 118:529-535.
7. Gulley ML, Nicholls JM, Schneider BG, Amin MB, Ro JY, Geradts J. 1998. Nasopharyngeal carcinomas frequently lack the p16/ MTS1 tumor suppressor protein but consistently express the retinoblastoma gene product. Am J Pathol 152:865-869.
8. Hayashi N, Sugimoto Y, Tsuchiya E, Ogawa M, Nakamura Y. 1994. Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK41 (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem Biophys Res Commun 202:1426-1430.
9. Hebert J, Cayuela JM, Berkeley J, Sigaux F. 1994. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T-but not from B-cell lineage acute lymphoblastic leukemias. Blood 84:4038-4044.
10. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. 1996. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821-9826.
11. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH, Jr, Tucker MA, Dracopoli NC. 1994. Germline p16 mutations in familial melanoma. Nat Genet 8:15-21.
12. Kamb A. 1998. Cyclin-dependent kinase inhibitors and human cancer. Curr Top Microbiol Immunol 227:139-148.
13. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ. 1997. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91:649-659.
14. Klangby U, Okan I, Magnusson KP, Wendland M, Lind P, Wiman KG. 1998. p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma. Blood 91:1680-1687.
15. Kovar H, Jug G, Aryee DN, Zoubek A, Ambros P, Gruber B, Windhager R, Gadner H. 1997. Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 15:2225-2232.
16. Okuda T, Shurtleff SA, Valentine MB, Raimondi SC, Head DR, Behm F, Curcio-Brint AM, Liu Q, Pui CH, Sherr CJ, et al. 1995. Frequent deletion of p16INK4a/MTS1 and p15INK4b/MTS2 in pediatric acute lymphoblastic leukemia. Blood 85:2321-2330.
17. Patino-Garcia A, Sierrasesumaga L. 1997. Analysis of the p16INK4 and TP53 tumor suppressor genes in bone sarcoma pediatric patients. Cancer Genet Cytogenet 98:50-55.
18. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. 1995. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993-1000.
19. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. 1996. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85:27-37.
20. Sherr CJ. 1996. Cancer cell cycles. Science 274:1672-1677.
21. Sherr CJ, Roberts JM. 1999. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501-1512.
22. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN. 1996. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56:150-153.
23. Zariwala M,. Xiong Y. 1996. Lack of mutation in the cyclin-dependent kinase inhibitor, p19INK4d, in tumor-derived cell lines and primary tumors. Oncogene 13:2033-2038.
24. Zhang Y, Xiong Y, Yarbrough WG. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725-734.